ASND

Ascendis Pharma A/S Sponsored ADR · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website ascendispharma.com
Employees(FY) 797
ISIN US04351P1012

Performance

+4.39%

+9.59%

-11.11%

+10.71%

+8.28%

YTD

+12.56%

Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Advanced Technical Analysis

Technical Analysis of ASND 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Oscillators Score of 43 suggests a neutral stance that may warrant caution. Overall, the Technical Score of 66 reinforces a generally positive outlook, though investors should remain mindful of potential fluctuations indi...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of ASND

Stock Rank

Recent News & Updates

2024-12-19 08:30
YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults(GlobeNewswire)
2024-12-18 19:30
YORVIPATH (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in Adults(Globenewswire)
2024-12-18 06:28
Ascendis Pharma Finalizes Key Collaboration with Novo Nordisk(TipRanks)
2024-12-16 08:30
New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26(GlobeNewswire)
2024-12-15 19:30
New InsiGHTS Trial of TransCon hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26(Globenewswire)
2024-12-12 16:42
Ascendis Pharma's Supplemental BLA for Adult Growth Hormone Deficiency Drug Accepted by FDA(MT Newswires)
2024-12-12 16:01
FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency(GlobeNewswire)
2024-12-12 09:06
Exploring Three High Growth Tech Stocks in the United States(Simply Wall St.)
2024-12-12 03:01
FDA Accepts Ascendis Pharma's Supplemental Biologics License Application for TransCon hGH for the Treatment of Adults with Growth Hormone Deficiency(Globenewswire)
2024-12-11 11:09
Er-Kim and Ascendis’ endocrine therapy agreement extended in Eurasia(Pharmaceutical Technology)
2024-12-09 18:00
Er-Kim Extends Exclusive Distribution Agreement with Ascendis Pharma A/S to Expand Commercialization of Its Endocrinology Portfolio to Eurasian Markets(Globenewswire)
2024-11-14 16:16
Ascendis Pharma Q3 Loss Narrows, Revenue Rises(MT Newswires)
2024-11-14 16:01
Ascendis Pharma Reports Third Quarter 2024 Financial Results(GlobeNewswire)
2024-11-14 03:01
Ascendis Pharma Reports Third Quarter 2024 Financial Results(Globenewswire)
2024-11-07 16:01
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024(GlobeNewswire)
2024-11-07 03:01
Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024(Globenewswire)
2024-11-06 13:02
High Growth Tech Stocks In The United States To Watch(Simply Wall St.)
2024-11-05 12:12
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RA(Pharmaceutical Technology)
2024-11-05 10:00
Novo Nordisk Secures License for Ascendis Pharma's Obesity Drug Technology(GuruFocus.com)
2024-11-05 07:10
Ascendis Pharma granted Novo exclusive worldwide license to TransCon platform(TipRanks)
2024-11-04 18:27
Ascendis Pharma and Novo Nordisk Join Forces(Yahoo Finance)
2024-11-04 15:30
Ozempic maker Novo Nordisk is working on a once-monthly weight-loss drug(Quartz)
2024-11-04 13:34
Wegovy Manufacturer Inks Multi-Million Deal For Monthly Obesity Drug(Benzinga)
2024-11-04 11:01
Ascendis, Novo Nordisk to Develop, Commercialize Products in Metabolic, Cardiovascular Diseases(MT Newswires)
2024-11-04 07:00
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases(GlobeNewswire)
2024-11-03 18:00
Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases(Globenewswire)
2024-10-01 10:13
Ascendis Pharma submits sBLA for growth hormone deficiency therapy(Pharmaceutical Technology)
2024-10-01 06:04
High Growth Tech Stocks To Watch In October 2024(Simply Wall St.)
2024-09-30 09:23
Ascendis Pharma Submits Supplemental Biologics License Application for Pediatric Growth Hormone Drug(MT Newswires)
2024-09-30 08:30
Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone Deficiency(GlobeNewswire)

Page 1 of 10

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.